Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults.
Mark R LitzowZhuoxin SunRyan J MattisonElisabeth M PaiettaKathryn G RobertsYanming ZhangJanis RacevskisHillard M LazarusJacob M RoweDaniel A ArberMatthew J WieduwiltMichaela LiedtkeJulie BergeronBrent L WoodYaqi ZhaoGang WuTi-Cheng ChangWenchao ZhangKeith W PratzShira N DinnerNoelle FreySteven D GoreBhavana BhatnagarEhab L AtallahGeoffrey L UyDeepa JeyakumarTara L LinCheryl L WillmanDaniel J DeAngeloShejal B PatelMichelle A ElliottAnjali S AdvaniDimitrios TzachanisPankit VachhaniRupali R BhaveElad SharonRichard F LittleHarry P ErbaRichard M StoneSelina M LugerCharles G MullighanMartin S TallmanPublished in: The New England journal of medicine (2024)
The addition of blinatumomab to consolidation chemotherapy in adult patients in MRD-negative remission from BCP-ALL significantly improved overall survival. (Funded by the National Institutes of Health and others; E1910 ClinicalTrials.gov number, NCT02003222.).